Carl W. Dieffenbach, Ph.D.Director

Division of AIDS, NIAIDJuly 2, 2013

HIV Vaccine and Future Strategies

This session will review past HIV vaccine efforts, as well as novel viral vectors and advances in the design of vaccines to induce neutralizing antibodies. A panel will discuss options to accelerate the development of a much needed HIV vaccine.

ALVAC pox-based prime boost programme (RV144) Punnee Pitisuttithum, Thailand State of the art findings on HIV vaccines Glenda Gray, South Africa

B cell response to vaccine candidates; antibody-based approaches Dennis Burton, United StatesIssues of engagement with populations at risk in HIV vaccine trials Mitchell Warren, United StatesDebate on future HIV vaccine strategies, including T response/other immune responses to vaccines Marcus Altfeld, United StatesDennis Burton, United StatesGlenda Gray, South AfricaPunnee Pitisuttithum, ThailandMitchell Warren, United States

HIV Vaccine Efficacy Trials

NOTE: Phambili (HVTN 503) began to explore a regime similar to STEP in South Africa (not included).

No